Clinical Trials

Do you or your child have severe asthma that is not easily controlled by inhaled corticosteroids? This study evaluates the use of five different asthma medicines to treat adults and adolescents with severe asthma. To participate in this study, you or your child must be 12 years old or older. This study takes place in multiple locations across the United States.

Are you a 30- to 55-year-old smoker or non-smoker who would like to support better understanding of COPD risk factors? This study aims to find early signs of COPD in adults who have a high risk of this condition. Researchers will compare results from questionnaires, lung tests, and other tests in people who smoke and in people who do not smoke to look for factors that predict which people will develop COPD. To participate in this study, you must either currently smoke or have no history of smoking. This study takes place in multiple locations in the United States.

Have you or your child been diagnosed with cystic fibrosis, and would you like to support better diagnosis of lung infections? This study is exploring new ways to diagnose bacterial lung infections in people who have cystic fibrosis. The study will test whether analyzing a participant’s breath and sputum samples can help diagnose infections. Participants in this study must be at least 3 years old. This study is taking place in multiple locations in the United States.

Are you a woman 18 years old or older who has been diagnosed with LAM? This study is examining whether long-term treatment with medicine called sirolimus can stop lung damage in women who have LAM. This study takes place at multiple locations in the United States.

Do you or your child have symptoms of a serious lung disease but no diagnosis? This study aims to develop new ways to diagnose primary ciliary dyskinesia (PCD) and primary immune deficiency (PID), two conditions that can have similar symptoms. Researchers will combine information from genetic testing, lung imaging, and lung function tests to diagnose ant tell the difference between these two conditions. Participants in this study must be 5 to 45 years old. This study is taking place at multiple locations in the United States and in Canada.

Are you a shift worker who regularly gets 7 to 9 hours of sleep each day? This study is looking at whether shift work negatively affects overall bone health. The study will test whether resuming and maintaining a daily schedule that aligns with the environment, after a period of night shift work, can help reverse bone problems. To participate in this study, you must be 20 to 40 years old. This study takes place in Aurora, Colorado.

Demonstrating the feasibility, effectiveness, and cost-effectiveness of electronically delivered smoking cessation interventions via patient portals in Federally Qualified Health Care (FQHC) settings has the potential for wide-spread dissemination and significant public health impact. on patient populations with demonstrated high rates of smoking.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

Is your family from India, Pakistan, Bangladesh, Nepal, or Sri Lanka? If so, you may be able to participate in a clinical study looking at cardiovascular disease, such as heart disease and stroke among people of South Asian descent. Participants must be between 40 and 84 years old and have no history of heart attack or stroke, heart failure, angina, or atrial fibrillation. This study is taking place in San Francisco, California, Chicago, Illinois, and New York City, New York.

The main goal of this study is to determine whether the treatment will lead to a complete absence of severe vaso-occlusive events (VOEs) in patients with severe SCD.